Ipsen Closes ImCheck Therapeutics Purchase

MT Newswires · 1d ago
12:02 AM EST, 12/16/2025 (MT Newswires) -- Ipsen (IPN.PA) completed the acquisition of private French biotechnology company ImCheck Therapeutics, according to a Monday release. The French biopharmaceutical company agreed to pay ImCheck shareholders 350 million euros and an additional contingent consideration of up to 1 billion euros, subject to certain regulatory and sales milestones. Belgian investment company Gimv (GIMB.BR) is among the sellers.